Presentation is loading. Please wait.

Presentation is loading. Please wait.

Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene?  Sumeet Gupta, MPharm, PhD,

Published byBrianne Newton Modified over 6 years ago

Similar presentations

Presentation on theme: "Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene?  Sumeet Gupta, MPharm, PhD,"— Presentation transcript:

1 Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene?  Sumeet Gupta, MPharm, PhD, Vikas Jhawat, MPharm, PhD Student  Value in Health Regional Issues  Volume 12, Pages (May 2017) DOI: /j.vhri Copyright © Terms and Conditions

2 Fig. 1 Pathophysiological association between hypertension and diabetes. RAAS, renin-angiotensin-aldosterone system. Value in Health Regional Issues  , 90-98DOI: ( /j.vhri ) Copyright © Terms and Conditions

3 Fig. 2 Relative risk of NOD in comparison with placebo reported by different studies. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CHARM, Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity; DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication; EWPHE, European Working Party on High Blood Pressure in the Elderly; HOPE, Heart Outcomes Prevention Evaluation; NOD, new-onset diabetes; PEACE, Prevention of Events with Angiotensin-Converting Enzyme Inhibition Trial; SHEP, Systolic Hypertension in the Elderly Program; SOLVD, Studies of Left Ventricular Dysfunction; TRANSCEND, Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiovascular Disease. Value in Health Regional Issues  , 90-98DOI: ( /j.vhri ) Copyright © Terms and Conditions

4 Fig. 3 Relative risk of NOD in comparison with BB/diuretics reported by different studies. AASK, African American Study of Kidney Disease and Hypertension; ACEI, angiotensin-converting enzyme inhibitor; ALLHAT, Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial; ALPINE, Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation; ARB, angiotensin receptor blocker; ASCOT-BPLA, Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm; BB, β-blocker; CAPPP, Captopril Prevention Project; CCB, calcium channel blocker; INSIGHT, Intervention as a Goal in Hypertension Treatment; INVEST, International Verapamil-Trandolapril Study; LIFE, Losartan Intervention for Endpoint Reduction; NOD, new-onset diabetes; NORDIL, Nordic Diltiazem Study; STOP-2, Swedish Trial in Old Patients with Hypertension-2. Value in Health Regional Issues  , 90-98DOI: ( /j.vhri ) Copyright © Terms and Conditions

5 Fig. 4 Relative risk of NOD in comparison with CCB reported by different studies. AASK, African American Study of Kidney Disease and Hypertension; ACEI, angiotensin-converting enzyme inhibitor; ANBP2, Second Australian National Blood Pressure Study; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; NOD, new-onset diabetes; STOP-2, Swedish Trial in Old Patients with Hypertension-2; VALUE, Valsartan Antihypertensive Long-Term Use Evaluation. Value in Health Regional Issues  , 90-98DOI: ( /j.vhri ) Copyright © Terms and Conditions

6 Fig. 5 Antihypertensive therapy–induced risk of NOD via alpha adducin gene polymorphism. GFR, glomerular filtration rate; NOD, new-onset diabetes. Value in Health Regional Issues  , 90-98DOI: ( /j.vhri ) Copyright © Terms and Conditions

7 Fig. 6 Antihypertensive therapy–induced risk of NOD via ACE gene polymorphism. ACE, angiotensin-converting enzyme; NOD, new-onset diabetes. Value in Health Regional Issues  , 90-98DOI: ( /j.vhri ) Copyright © Terms and Conditions

8 Fig. 7 Antihypertensive therapy–induced risk of NOD via IRS-1 gene polymorphism. IRS-1, insulin receptor substrate 1; NOD, new-onset diabetes. Value in Health Regional Issues  , 90-98DOI: ( /j.vhri ) Copyright © Terms and Conditions

Download ppt "Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene?  Sumeet Gupta, MPharm, PhD,"

Similar presentations

ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.

ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.
BACK TO BASICS: PHARMACOLOGY CHAD C. CRIPE, MD Department of Anesthesiology & Critical Care Medicine Division of Cardiothoracic Anesthesiology The Children’s.

BACK TO BASICS: PHARMACOLOGY CHAD C. CRIPE, MD Department of Anesthesiology & Critical Care Medicine Division of Cardiothoracic Anesthesiology The Children’s.
Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP

Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
 Hypertension : BPDIASTOLIC SYSTOLIC Normal< 130< 85 Mild hypertension 140 - 15990 - 99 Moderate hypertension 160 - 179100 - 109 Severe Hypertension 180.

 Hypertension : BPDIASTOLIC SYSTOLIC Normal< 130< 85 Mild hypertension Moderate hypertension Severe Hypertension 180.
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal

Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
The Renin-Angiotensin System

The Renin-Angiotensin System
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:2981-2997.

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Is there evidence to justify different claims for different drug classes? Presentation to: Cardiovascular & Renal Drugs Advisory Committee Food & Drug.

Is there evidence to justify different claims for different drug classes? Presentation to: Cardiovascular & Renal Drugs Advisory Committee Food & Drug.
ALLHAT 6/5/2006 - 1 CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
6/5/2006 - 1 1 CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Dr.AZDAKI (cardiologist).   Initial monotherapy is successful in many patients with mild primary hypertension (formerly called essential hypertension).

Dr.AZDAKI (cardiologist).   Initial monotherapy is successful in many patients with mild primary hypertension (formerly called "essential" hypertension).
Date of download: 6/28/2016 From: Drug Treatment of Hypertension in the Elderly: A Meta-Analysis Ann Intern Med. 1994;121(5):355-362. doi:10.7326/0003-4819-121-5-199409010-00008.

Date of download: 6/28/2016 From: Drug Treatment of Hypertension in the Elderly: A Meta-Analysis Ann Intern Med. 1994;121(5): doi: /
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/AHA 2011 Expert Consensus Document on Hypertension.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/AHA 2011 Expert Consensus Document on Hypertension.
Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.

Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.
Management of progression of CKD 순천향 대학병원 신장내과 강혜란.

Management of progression of CKD 순천향 대학병원 신장내과 강혜란.
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.

Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.
Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.
Hypertension JNC VIII Guidelines.

Hypertension JNC VIII Guidelines.

Similar presentations

Ads by Google